PMGC's NorthStrive expands AI drug program with Yuva, advances four compounds

PMGC Holdings Inc.

NorthStrive (PMGC) and Yuva execute First Amendment launching three-phase Expansion Program for four AI-discovered compounds.
Program builds on July 1, 2026 Phase III results (significant ANT1 increases); ~6 months to lead compound nomination.
Amendment grants right of first refusal for exclusive cardiometabolic license beyond Cardiac Diseases and Obesity.
Company increased authorized shares to 1.5B (1B common, 500M preferred) via Certificate of Amendment, 60.34% approval.

item 1.01 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.